Referees 2023
(Source: Diabetologia)
Source: Diabetologia - February 13, 2024 Category: Endocrinology Source Type: research
A novel subpopulation of monocytes with a strong interferon signature indicated by SIGLEC-1 is present in patients with in recent-onset type 1 diabetes
Conclusions/interpretationOur study identified a novel group of SIGLEC-1+ monocytes that may serve as an important indicator for early diagnosis, activity assessment and monitoring of therapeutic efficacy in type 1 diabetes, and may also be a novel target for preventing and treating type 1 diabetes.Data availabilityRNA-seq data have been deposited in the GSA human database (https://ngdc.cncb.ac.cn/gsa-human/) under accession number HRA003649.Graphical Abstract (Source: Diabetologia)
Source: Diabetologia - February 13, 2024 Category: Endocrinology Source Type: research
Correction to: Dose –response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
(Source: Diabetologia)
Source: Diabetologia - February 13, 2024 Category: Endocrinology Source Type: research
Referees 2023
(Source: Diabetologia)
Source: Diabetologia - February 13, 2024 Category: Endocrinology Source Type: research
Harnessing the power of proteomics in precision diabetes medicine
AbstractPrecision diabetes medicine (PDM) aims to reduce errors in prevention programmes, diagnosis thresholds, prognosis prediction and treatment strategies. However, its advancement and implementation are difficult due to the heterogeneity of complex molecular processes and environmental exposures that influence an individual ’s disease trajectory. To address this challenge, it is imperative to develop robust screening methods for all areas of PDM. Innovative proteomic technologies, alongside genomics, have proven effective in precision cancer medicine and are showing promise in diabetes research for potential translat...
Source: Diabetologia - February 12, 2024 Category: Endocrinology Source Type: research
GLP-1 metabolite GLP-1(9 –36) is a systemic inhibitor of mouse and human pancreatic islet glucagon secretion
Conclusions/interpretationWe conclude that the GLP-1 metabolite GLP-1(9 –36) is a systemic inhibitor of glucagon secretion. We propose that the increase in circulating glucagon observed following genetic/pharmacological inactivation of glucagon signalling in mice and in people with type 2 diabetes reflects the removal of GLP-1(9–36)’s glucagonostatic action.Graphical Abstract (Source: Diabetologia)
Source: Diabetologia - February 11, 2024 Category: Endocrinology Source Type: research
Advances and challenges in measuring hepatic glucose uptake with FDG PET: implications for diabetes research
AbstractThe liver plays a crucial role in the control of glucose homeostasis and is therefore of great interest in the investigation of the development of type 2 diabetes. Hepatic glucose uptake (HGU) can be measured through positron emission tomography (PET) imaging with the tracer [18F]-2-fluoro-2-deoxy-d-glucose (FDG). HGU is dependent on many variables (e.g. plasma glucose, insulin and glucagon concentrations), and the metabolic state for HGU assessment should be chosen with care and coherence with the study question. In addition, as HGU is influenced by many factors, protocols and measurement conditions need to be sta...
Source: Diabetologia - February 11, 2024 Category: Endocrinology Source Type: research
NRF2 is required for neonatal mouse beta cell growth by maintaining redox balance and promoting mitochondrial biogenesis and function
Conclusions/interpretationOur study highlights NRF2 as an essential transcription factor for maintaining neonatal redox balance, mitochondrial biogenesis and function and beta cell growth, and for preserving functional beta cell mass in adulthood under metabolic stress.Data availabilitySequencing data are available in the NCBI Gene Expression Omnibus, accession number GSE242718 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE242718).Graphical Abstract (Source: Diabetologia)
Source: Diabetologia - February 11, 2024 Category: Endocrinology Source Type: research
The impact of taxing sugar-sweetened beverages on diabetes: a critical review
AbstractThe global burden of type 2 diabetes is increasing at an alarming rate, fuelled by the obesity epidemic, with significant associated health and economic consequences and apparent inequalities. Sugar-sweetened beverages (SSBs) are a major source of added sugars in diets worldwide and have been linked to an increased risk of type 2 diabetes through a variety of mechanisms, including excess weight. Taxing SSBs has become a promising public health strategy to reduce consumption and mitigate the burden of type 2 diabetes. A substantial body of evidence suggests that SSB taxes lead to increased prices and subsequent redu...
Source: Diabetologia - February 11, 2024 Category: Endocrinology Source Type: research
Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study
Conclusions/interpretationIn individuals with NAFLD and type 2 diabetes, GLP-1RAs are associated with lower incidences of adverse CVEs and all-cause mortality compared with metformin or other second- and third-line glucose-lowering medications. However, there was no significant difference in adverse CVEs or all-cause mortality when compared with those taking SGLT2 inhibitors.Graphical Abstract (Source: Diabetologia)
Source: Diabetologia - February 11, 2024 Category: Endocrinology Source Type: research
Twenty years of participation of racialised groups in type 2 diabetes randomised clinical trials: a meta-epidemiological review
Conclusions/interpretationRacialised participants are under-represented in government- and industry-funded type 2 diabetes trials. Strategies to improve recruitment and enrolment of racialised participants into RCTs should be developed.RegistrationOpen Science Framework registration no. f59mk (https://osf.io/f59mk)FundingThe authors received no financial support for this research or authorship of the article.Graphical Abstract (Source: Diabetologia)
Source: Diabetologia - February 11, 2024 Category: Endocrinology Source Type: research
Maternal and neonatal outcomes according to the timing of diagnosis of hyperglycaemia in pregnancy: a nationwide cross-sectional study of 695,912 deliveries in France in 2018
Conclusions/interpretationCompared with GDM22 –30, overt diabetes, GDM<22 and, to a lesser extent, GDM>30 were associated with poorer maternal –fetal outcomes.Graphical Abstract (Source: Diabetologia)
Source: Diabetologia - February 11, 2024 Category: Endocrinology Source Type: research
Type 2 diabetes and succinate: unmasking an age-old molecule
AbstractBeyond their conventional roles in intracellular energy production, some traditional metabolites also function as extracellular messengers that activate cell-surface G-protein-coupled receptors (GPCRs) akin to hormones and neurotransmitters. These signalling metabolites, often derived from nutrients, the gut microbiota or the host ’s intermediary metabolism, are now acknowledged as key regulators of various metabolic and immune responses. This review delves into the multi-dimensional aspects of succinate, a dual metabolite with roots in both the mitochondria and microbiome. It also connects the dots between succi...
Source: Diabetologia - February 11, 2024 Category: Endocrinology Source Type: research
MTNR1B genotype and effects of carbohydrate quantity and dietary glycaemic index on glycaemic response to an oral glucose load: the OmniCarb trial
Conclusions/interpretationOur study shows that carrying the risk G allele ofMTNR1B-rs10830963 is associated with greater glycaemic responses after consuming a diet with high carbohydrates and high GI levels. Reducing GI in a high-carbohydrate diet may decrease post-OGTT glucose concentrations among the risk G-allele carriers.Graphical Abstract (Source: Diabetologia)
Source: Diabetologia - February 11, 2024 Category: Endocrinology Source Type: research
Glucagon-like peptide-1 receptor agonists reverse nerve morphological abnormalities in diabetic peripheral neuropathy
Conclusions/interpretationThis study demonstrates the efficacy of GLP-1 RAs in improving neuropathy outcomes, evidenced by improvements in mainly structural and morphological measures and supported by electrophysiological and clinical endpoints. Future studies, incorporating quantitative sensory testing and measurement of intraepidermal nerve fibre density, are needed to investigate the benefits for small fibre function and structure.Graphical Abstract (Source: Diabetologia)
Source: Diabetologia - February 11, 2024 Category: Endocrinology Source Type: research
